A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
DRUG: HLX43 DOSE 1|DRUG: HLX43 DOSE 2
ORR, Objective response rate (ORR) (assessed by the Independent Radiology Review Committee \[IRRC\] as per RECIST v1.1)., From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
ORR, Objective response rate (ORR) (assessed by the investigator as per RECIST v1.1)., From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months|PFS, Progression-free survival (PFS) (assessed by the IRRC and the investigator as per RECIST v1.1), From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months|OS, Overall survival (OS), From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months|Incidence and severity of adverse events (AEs), severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version \[v\] 5.0, vital signs and clinical laboratory test results, From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
This study is an open-label phase II clinical study to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with advanced non-small cell lung cancer (NSCLC). In this study, eligible subjects will be randomized at 1:1 ratio, and the patients will be administered with HLX43 at different doses via intravenous infusion.